Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Display:
Weinreich et al., "REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19," 2 Dec
Covid-19-related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%) (relative risk reduction [1 minus the relative risk], 71.3%; P<0.001); these outcomes occurred in 7 of 736 patients in the REGEN-COV 1200-mg group (1.0%) and in 24 of 748 patients in the placebo group who underwent randomization concurrently (3.2%) (relative risk reduction, 70.4%; P=0.002).
[...]
CONCLUSIONS
REGEN-COV reduced the risk of Covid-19-related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04425629. opens in new tab.)
archived WHO Fri Sep 24th, 2021 monoclonal approval
by Cat on Thu Dec 2nd, 2021 at 01:01:49 AM EST
[ Parent ]

Others have rated this comment as follows:

Display:

Top Diaries

Occasional Series